Hypermarcas (OTCMKTS:HYPMY – Get Free Report) will likely be releasing its results after the market closes on Wednesday, November 11th. Analysts expect Hypermarcas to announce earnings of $0.14 per share and revenue of $450.75 million for the quarter.
Hypermarcas Trading Up 2.1%
Shares of HYPMY stock opened at $4.11 on Tuesday. The company has a 50 day moving average of $4.64 and a 200-day moving average of $4.41. The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50. Hypermarcas has a 12-month low of $3.39 and a 12-month high of $5.77. The firm has a market cap of $2.89 billion, a P/E ratio of 7.80 and a beta of 0.78.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.
Hypermarcas Company Profile
Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories.
Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo QuĂmica and Mantecorp.
The company is based in Brazil and serves the domestic market through its pharmaceutical operations.
Further Reading
- Five stocks we like better than Hypermarcas
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
